Investment Summary |
|
|---|---|
| Date | 2020-06-09 |
| Target | Bioskryb |
| Sector | Life Science |
| Investor(s) | Anzu Partners |
| Deal Type | Venture |
SEARCH BY
| Category | Growth Capital Firm |
|---|---|
| Founded | 2014 |
| PE ASSETS | 1.0B USD |
| Size | Middle-Market |
| Type | Sector Agnostic |
Anzu Partners is a venture capital and private equity firm that looks to develop and commercialize technological advancements in manufacturing, materials, monitoring/measurement, and modeling. This includes 3D printing, robotics, nanotechnology, composites, sensors, AI, and analytics. Anzu Partners was formed in 2014 and is headquartered in Boston, Massachusetts.
| DEAL STATS | # |
|---|---|
| Overall | 18 of 36 |
| Sector: Life Science M&A | 6 of 11 |
| Type: Venture M&A Deals | 18 of 32 |
| State: North Carolina M&A | 1 of 2 |
| Country: United States M&A | 16 of 30 |
| Year: 2020 M&A | 4 of 9 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2020-06-09 |
BioFlyte
Albuquerque, New Mexico, United States BioFlyte is a biodefense and microbial identification company that is commercializing a revolutionary new class of fieldable biological threat collection, detection, and identification solutions. BioFlyte is based in Albuquerque, New Mexico. |
Buy | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2020-07-01 |
InterVenn Biosciences
South San Francisco, California, United States InterVenn Biosciences utilizes a proprietary glycoproteomic biomarker interrogation platform using AI and mass spectrometry for next-gen precision medicine. The company is working to find new solutions in ovarian, pancreatic, liver, prostate, and kidney cancer, together with applications from the Vista suite of solutions for treatment and monitoring, immune profiling, patient stratification, and disease progression. InterVenn Biosciences was founded in 2017 and is based in South San Francisco, California. |
Buy | - |
